Nurix Therapeutics, Inc. Common stock
NRIXStock
$23.07+81.09%52W
Market Cap$2.48B
P/E—
Div yield—
Beta1.77
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)23.17%
Price vs S&P 500 (4W)35.26%
VGM Score42.21
Market Capitalization$2.48B
Earnings Surprise History
Q2 25-0.52est. -0.74
Q3 25-1.03est. -0.86
Q4 25-0.82est. -0.89
Q1 26-0.79est. -0.77
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.30
4.30
4.30
4.23
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRIXNurix Therapeutics, Inc. Common stock | F | D | B | $23.07 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and inflammatory diseases using an AI-enhanced discovery platform. The company's pipeline includes candidates such as Bexobrutideg and Zelebrudomide that target specific disease-causing proteins in immune and oncology-related pathways.